Xi, C.; Palani, C.; Takezaki, M.; Shi, H.; Horuzsko, A.; Pace, B.S.; Zhu, X.
Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease. Antioxidants 2024, 13, 337.
https://doi.org/10.3390/antiox13030337
AMA Style
Xi C, Palani C, Takezaki M, Shi H, Horuzsko A, Pace BS, Zhu X.
Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease. Antioxidants. 2024; 13(3):337.
https://doi.org/10.3390/antiox13030337
Chicago/Turabian Style
Xi, Caixia, Chithra Palani, Mayuko Takezaki, Huidong Shi, Anatolij Horuzsko, Betty S. Pace, and Xingguo Zhu.
2024. "Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease" Antioxidants 13, no. 3: 337.
https://doi.org/10.3390/antiox13030337
APA Style
Xi, C., Palani, C., Takezaki, M., Shi, H., Horuzsko, A., Pace, B. S., & Zhu, X.
(2024). Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease. Antioxidants, 13(3), 337.
https://doi.org/10.3390/antiox13030337
